Lumosa Therapeutics (6535) announced the approval for dosing regimen patent of its LT3001, a novel therapeutics for acute ischemic stroke, from the USPTO, extending protection through 2042 and completing a three-part intellectual property framework covering compound, formulation and administration. The patent defines clinically validated dosing and regimens, strengthening market exclusivity, raising barriers to generic competition, and enhancing its position in global licensing discussions. LT3001, which combines thrombolytic and neuroprotective mechanisms, has received FDA Fast Track designation and continues to advance in clinical development and partnering efforts.